Please enable Javascript
An official publication of
The HemOnc Pulse
Meeting News
The HemOnc Pulse Live
Video Insights
In Print
Subscribe
Leukemia
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Lymphoma
Aggressive B-Cell Lymphoma
Hodgkin Lymphoma
Indolent B-Cell Lymphoma
Mantle Cell Lymphoma
T-Cell Lymphoma
MPN
Myelofibrosis
Polycythemia Vera
MDS
Myeloma
Transplantation & Cellular Therapy
Myelofibrosis
The latest news, research, and perspectives in myelofibrosis (MF). A primary subtype of myeloproliferative neoplasms (MPNs), this rare blood cancer scars the bone marrow so that it cannot properly produce blood cells.
Advertisement
Pacritinib Superior to Best Available Therapy for Myelofibrosis Patients With Thrombocytopenia, Anemia
Melissa Badamo
Myelofibrosis
|
November 4, 2024
Pacritinib demonstrated superiority to best available therapy for spleen volume reduction, total symptom score, and more.
Read More
What Are Potential Barriers to HSCT in Myelofibrosis?
Melissa Badamo
Myelofibrosis
|
November 13, 2024
Patients with splenomegaly are more likely to be referred for HSCT.
Read More
Selinexor Plus Ruxolitinib Reduces Symptom Burden in Myelofibrosis
Melissa Badamo
Myelofibrosis
|
November 4, 2024
Selinexor plus ruxolitinib was well tolerated, reduced symptom burden, and led to spleen volume reduction.
Read More
Pacritinib Improves Thrombocytopenia, Anemia in Myelofibrosis
Melissa Badamo
Myelofibrosis
|
November 4, 2024
One year of pacritinib treatment stabilized or improved thrombocytopenia and anemia in patients with myelofibrosis.
Read More
Pacritinib Improves Symptom Relief in Patients With Myelofibrosis Requiring RBC Transfusions
Cailin Conner
Myelofibrosis
|
October 8, 2024
The phase III PERSIST-2 study compared symptom results from pacritinib with those of best available therapy and ruxolitinib.
Read More
Study Highlights Genomic, Laboratory Differences in Myelofibrosis Treated With Pacritinib Versus Momelotinib
Cailin Conner
Myelofibrosis
|
October 8, 2024
Patients' genomic profiles and baseline laboratory values have implications for their treatment outcomes with these agents.
Read More
Advertisement
Study Validates Prognostic Models, Genetic Markers in Patients With Myelofibrosis
Cailin Conner
Myelofibrosis
|
October 8, 2024
The International Prognostic Scoring System, Dynamic International Prognostic Scoring System, and other models were applied.
Read More
Momelotinib, Pacritinib Exhibit Improved Outcomes, Low Discontinuation Rates in Myelofibrosis With Cytopenias
Cailin Conner
Myelofibrosis
|
October 9, 2024
A retrospective study found momelotinib plus pacritinib led to reduced need for red blood cell transfusion in patients.
Read More
Transfusion Burden Revealed in Patients With Myelofibrosis, Anemia on Ruxolitinib
Andrew Moreno
Myelofibrosis
|
September 30, 2024
A real-world retrospective study evaluated transfusion dependent or nondependent patients at ruxolitinib initiation.
Read More
Routine DIC Evaluations Have Questionable Clinical Value in Stable Myelofibrosis
Andrew Moreno
Myelofibrosis
|
September 27, 2024
Management of asymptomatic, clinically stable disease is not necessarily improved by implementing routine hemostasis tests.
Read More
Anti-Hemojuvelin Agent Counters Anemia in Myelofibrosis
Andrew Moreno
Myelofibrosis
|
September 27, 2024
Investigational agent DISC-0974 produced anemia response independent of patient transfusion dependency or JAK inhibitor use.
Read More
Addition of BET Inhibitor to Ruxolitinib Yields Significant Response in Myelofibrosis
Andrew Moreno
Myelofibrosis
|
September 26, 2024
A study observed that addition of pelabresib to ruxolitinib led to bone marrow microenvironment improvement.
Read More
Dr. Bose on JAK Inhibitor Optimization, Trial Updates in Myelofibrosis
Prithviraj Bose, MD
Myelofibrosis
|
September 25, 2024
An expert on myelofibrosis comments on promising results from current trials and on the need for useful clinical biomarkers.
View More
Study Outlines Progression Risk from PV to Myelofibrosis
Melissa Badamo
Myelofibrosis
|
September 13, 2024
History of thrombotic events, hematocrit ≤0.45 L/L, and JAK2 p.V617F were identified as risk factors for progression.
Read More
Study Investigates LOXL2 Expression in Primary Myelofibrosis Pathogenesis
Melissa Badamo
Myelofibrosis
|
September 13, 2024
LOXL2 upregulation is associated with key inflammatory signaling pathways in primary myelofibrosis.
Read More
Long-Term Selinexor Is ‘Feasible’ in Patients With Myelofibrosis
Melissa Badamo
Myelofibrosis
|
September 13, 2024
Treatment with selinexor reduced hepcidin and pro-inflammatory cytokines in patients with myelofibrosis.
Read More
Patients With Myelofibrosis, Anemia Have Higher Rates of Comorbidities, Severe Thrombocytopenia
Melissa Badamo
Myelofibrosis
|
September 13, 2024
The rates of baseline comorbidities and constitutional symptoms were higher in patients with anemia versus those without.
Read More
New or Worsening Anemia Does Not Impact Clinical Benefit of Ruxolitinib in Patients With Myelofibrosis
Rob Dillard
Myelofibrosis
|
September 10, 2024
New or worsening anemia following initiation of ruxolitinib does not appear to diminish clinical benefit.
Read More
Hemoglobin Improvement Associated With Improved PROs in Myelofibrosis Patients With Anemia
Rob Dillard
Myelofibrosis
|
September 10, 2024
Hemoglobin improvement at week 24 after transfusion is associated with improved HRQOL in myelofibrosis and anemia.
Read More
Study Analyzes Progression from Essential Thrombocythemia to Myelofibrosis
Rob Dillard
Myelofibrosis
|
September 10, 2024
Prospective analysis suggest that 4.3% of patients with ET progressed to myelofibrosis over five years of follow up.
Read More
Load More
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACP
Editor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MD
Associate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MD
Executive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MD
Associate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MD
Associate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MD
Associate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPH
Associate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer